Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/35895
Title: Targeting Polo-like Kinase 1 in Glioma Propagating Cells
Authors: FOONG SHU FEN CHARLENE
Keywords: Stem cells, Cancer and cancer drugs, Gene expression, Cell-based assays, Polo-like kinase 1
Issue Date: 23-Jul-2012
Source: FOONG SHU FEN CHARLENE (2012-07-23). Targeting Polo-like Kinase 1 in Glioma Propagating Cells. ScholarBank@NUS Repository.
Abstract: Patient-derived glioma-propagating cells (GPCs) possess karyotypic aberrations typical of the primary tumor, extensive self-renewal and serial tumor-propagating ability, and reform tumor xenografts that mirror the patients? original profiles. To explore GPC regulatory pathways, we performed a small molecule screen which identified Plk1 as a potential candidate. Plk1 inhibition through pharmacological and genetic approaches led to significant reduction in GPC frequency and proliferation, and G2/M cell cycle arrest with concomitant apoptosis. Importantly, tumor-bearing mice intravenously treated with a Plk1 small molecule inhibitor displayed reduced tumor volumes with increased necrosis. To derive clinical relevance, we tapped into public glioma databases using bioinformatics methods and showed that high PLK1-coexpressed genes stratified patients for poor survival independently of current clinical indicators. Our data implicate Plk1 as an essential regulator of GPC and consequently tumor growth. Furthermore, our data highlights the limitation of relying solely on morphology-based histological methods to diagnose and subsequently treat patients.
URI: http://scholarbank.nus.edu.sg/handle/10635/35895
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
FoongSFC A0050359.pdf3.92 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

215
checked on Dec 11, 2017

Download(s)

296
checked on Dec 11, 2017

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.